Department of Pharmacology and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Korea.
Br J Pharmacol. 2009 Dec;158(7):1743-52. doi: 10.1111/j.1476-5381.2009.00436.x.
Earlier we reported that 7,8-dihydro-8-oxo-deoxyguanosine (8-oxo-dG), an oxidatively modified guanine nucleoside, exerted anti-inflammatory activity through inactivation of the GTP binding protein, Rac. In the present study, the effects of 8-oxo-dG were investigated on responses to antigen challenge in sensitized mice, as Rac is also involved at several steps of the immune process including antigen-induced release of mediators from mast cells.
Mice were sensitized and challenged with ovalbumin without or with oral administration of 8-oxo-dG during the challenge. Effects of 8-oxo-dG were assessed by measuring lung function, cells and cytokines in broncho-alveolar lavage fluid (BALF) and serum levels of antigen-specific IgE. Rac activity in BALF cells was also measured.
8-oxo-dG inhibited the increased airway resistance and decreased lung compliance of sensitized and challenged mice to the levels of non-sensitized control mice and lowered the increased leukocytes particularly, eosinophils, in BALF. Furthermore, 8-oxo-dG suppressed allergy-associated immune responses, such as raised anti- ovalbumin IgE antibody in serum, increased expression of CD40 and CD40 ligand in lung, increased interleukin-4, -5, -13, interferon-gamma and tumour necrosis factor-alpha in BALF and mRNA levels of these cytokines in BALF cells, dose-dependently. The corresponding purine, 8-oxo-guanine, showed no effects in the same experiments. Finally, 8-oxo-dG, but not 8-oxo-guanine, inhibited the increased Rac activity in sensitized and challenged mice.
8-Oxo-dG had anti-allergic actions that might be mediated by Rac inactivation. This compound merits further evaluation of its therapeutic potential in allergic asthma.
我们之前曾报道过,氧化修饰的鸟嘌呤核苷 7,8-二氢-8-氧代-脱氧鸟苷(8-oxo-dG)通过使 GTP 结合蛋白 Rac 失活来发挥抗炎活性。在本研究中,我们研究了 8-oxo-dG 对致敏小鼠抗原挑战反应的影响,因为 Rac 也参与了免疫过程的多个步骤,包括抗原诱导肥大细胞释放介质。
小鼠在挑战期间用卵清蛋白致敏和挑战,同时口服 8-oxo-dG。通过测量肺功能、支气管肺泡灌洗液(BALF)中的细胞和细胞因子以及血清中抗原特异性 IgE 的水平来评估 8-oxo-dG 的作用。还测量了 BALF 细胞中的 Rac 活性。
8-oxo-dG 抑制了致敏和挑战的小鼠气道阻力增加和肺顺应性降低,使其恢复到非致敏对照小鼠的水平,并降低了 BALF 中增加的白细胞,特别是嗜酸性粒细胞。此外,8-oxo-dG 抑制了与过敏相关的免疫反应,例如血清中抗卵清蛋白 IgE 抗体的增加、肺中 CD40 和 CD40 配体表达的增加、BALF 中白细胞介素-4、-5、-13、干扰素-γ和肿瘤坏死因子-α的增加以及 BALF 细胞中这些细胞因子的 mRNA 水平,呈剂量依赖性。在相同的实验中,相应的嘌呤 8-氧代鸟嘌呤没有显示出任何作用。最后,8-oxo-dG 而非 8-oxo-guanine 抑制了致敏和挑战的小鼠中 Rac 活性的增加。
8-oxo-dG 具有抗过敏作用,可能通过 Rac 失活介导。该化合物值得进一步评估其在过敏性哮喘中的治疗潜力。